Cytomegalovirus immediate-early 2 mRNA (CMV IE2 mRNA)

Cytomegalovirus immediate-early 2 (IE2) mRNA is a pivotal viral transcript encoded by the UL122 gene of the Human Cytomegalovirus (HCMV) (Stinski & Isomura, 2008, Journal of Virology). It is expressed immediately upon viral entry into the host cell and serves as the template for the IE2 protein, a potent transcriptional activator required for the expression of early and late viral genes (UniProt P04439). Without the IE2 protein, HCMV cannot proceed with its replication cycle, making the mRNA an ideal target for antiviral intervention. This target is historically significant as the site of action for fomivirsen, the first antisense oligonucleotide drug approved by the FDA for the treatment of CMV retinitis (Perry & Barman, 1999, Drugs). Fomivirsen works by binding to the IE2 mRNA through complementary base pairing, which inhibits protein translation and may trigger RNase H-mediated degradation of the transcript (Roehr, 1998, Journal of the International Association of Physicians in AIDS Care). Although fomivirsen was eventually withdrawn from the market due to the advent of highly active antiretroviral therapy (HAART) reducing the incidence of CMV, the IE2 mRNA remains a well-validated target for inhibiting viral progression in immunocompromised individuals. Targeting this mRNA provides a mechanism to halt the viral life cycle at its earliest regulatory stage.

Other names

UL122 mRNAHuman cytomegalovirus IE2 mRNAHCMV IE2 mRNAIE86 mRNAImmediate-early protein 2 mRNA

Antisense oligonucleotide-mediated inhibition of translation and/or RNase H-dependent degradation of viral mRNA